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Modern human activity fueled by economic development is profoundly altering our relation-
ship with microorganisms. This altered interaction with microbes is believed to be the major
driving force behind the increased rate of emerging infectious diseases from animals. The
spate of recent infectious disease outbreaks, including Ebola virus disease and Middle East
respiratory syndrome, emphasize the need for development of new innovative tools to
manage these emerging diseases. Disseminating vaccines are one such novel approach to
potentially interrupt animal to human (zoonotic) transmission of these pathogens.
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Modern human activity is profoundly and irrever-
sibly changing our natural world.[1] In addition to
the more publicized global warming and mass
extinctions, human activity is altering our relation-
ship with microorganisms to far-reaching effect.
[2,3] The impact of this altered relationship can be
seen by the startling rise in the rate of emerging
infectious diseases (EIDs).[4] Increased global tra-
vel, agricultural expansion into wildlife habitats,
deforestation and urbanization are all driving
humans into greater and more intimate contact
with animal populations, creating greater oppor-
tunity for human exposure to new microbes.[3–6]
Although the particular animal species involved
may never be known,[7] the 2014/2015 Ebola
virus epidemic in West Africa shows that the
global community remains ill-prepared for EIDs.
[8,9] This lack of preparedness is multifactorial,
but we suggest it includes the current risk adverse
nature of scientific funding away from innovative
and novel, ‘high-risk, high-reward’ science (i.e.,
science with a high risk of failure, but which is
potentially transformative),[10] as well as insuffi-
cient allocation of resources toward the poorer
countries that represent the most likely sites of
future EIDs of global significance.[4] In the
words of Albert Einstein quoted in the recent
Advancing Research In Science and Engineering
report that highlighted the worrying shift towards
‘low-risk’ science [10]:
If at first the idea is not absurd, then there is
no hope for it.
Microbial movement into humans from ani-
mals (zoonotic transmission) has always been
responsible for the majority of EIDs, including
at one time EIDs that form such present day
matrix diseases as malaria falciparum,[11] measles
and TB.[12] For modern EIDs, it is estimated
that over 70% of zoonotic pathogens originate in
wildlife, entering either directly from wildlife
reservoirs, or indirectly via an intermediate
domestic animal host.[4,13] HIV, avian influ-
enza, Hendra and Nipah viruses, SARS and
MERS, and Ebola and Marburg filoviruses are
all examples of zoonoses currently emerging from
wildlife. All of these EIDs present a serious and
increasing threat to health, biosecurity and
economies worldwide. It is a sobering observation
that most modern EIDs were entirely unknown
before their entry into the human population.
This pattern of emergence of new pathogens of
global significance into humans from wildlife is
expected to continue.
Special Reports
www.tandfonline.com 10.1586/14760584.2016.1106942 © 2015 The Author(s). Published by Taylor & Francis. ISSN 1476-0584 31
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The task of identifying and preventing zoonoses is daunting,
particularly given that the emerging pathogen may be comple-
tely unknown. The availability of limited resources and alloca-
tion of these resources over short-term funding periods further
compounds the problem.[8,9] Recently, a landmark study from
Daszak and colleagues examining conditions associated with
emergence of >300 EIDs over the past 60 years highlighted
the ineffectiveness with which resources for control of EIDs
are being allocated.[4] Allowing for reporting bias, this study
indicated that emergence of pathogens from wildlife, which
represents the greatest threat to global health, is not uniform,
but instead is localized to distinct geographic ‘hotspots’ in
Africa, Asia and South America. These ‘high-risk’ EIDs were
also shown to be biased toward a few ‘high-value’ wildlife
species (bats, rodents and non-human primates (NHPs)). This
realization that global resources need to be allocated toward
countries that have the highest likelihood of high-risk EIDs
[4] has led to the recent implementation of surveillance pro-
grams (e.g., USAID Emerging Pandemic Threats (EPT) pro-
gram (superseded by EPT-2 in 2014)) targeting ‘high-value’
target wildlife species in ‘hotspot’ areas prone to EIDs.
However, the recent 2014/2015 Ebola virus epidemic empha-
sizes the need for further investment in such EID surveillance
and control programs.
Surveillance is only one component of a successful control
program. Following identification, an emerging pathogen must
then be controlled. For wildlife pathogens emerging through
intermediate domestic animal host species, such as Nipah virus
in swine or avian influenza in poultry, effective containment has
been achieved either by mass vaccination using conventional
vaccines, or by large-scale culling.[5,14] Although costly, the
demonstrated ability to successfully contain these EIDs at source
suggests the utility of these procedures for EID control in some
domestic animals.[5] In contrast, restricted accessibility and
idiosyncrasies of natural habitats present unique problems to
the control of pathogens within wildlife species. For example,
large-scale oral vaccination using vaccine-laden bait has been
highly successful in eliminating rabies in wild fox populations in
western Europe (for review, see [15]). Similarly, culling of
European badgers to control the epizootic spread of
Mycobacterium bovis to cattle has had some success in the con-
trol of bovine TB in Ireland and regions of the UK (for review,
see [16]). However, the effectiveness of badger culling is variable
and somewhat counterintuitively has also been associated with
increased, rather than decreased, bovine TB incidence in some
regions.[16] This unanticipated effect is believed to be due to
the increased movement of surviving badgers following disrup-
tion of their social groups (perturbation effect) [16] – with levels
of perturbation varying depending on landscape and intensity of
culling. Culling of foxes to combat rabies prior to implementa-
tion of mass vaccination similarly led to an increased incidence
of rabies in foxes.[15]
In non-temperate ‘hotspot’ regions of Africa, Asia and South
America, the ability to contain even known EIDs such as Ebola
virus in wildlife is currently not possible. Management of
diseases that involve livestock in these regions, such as Rift
Valley fever and Crimean Congo hemorrhagic fever, pose simi-
lar problems,[17,18] in that conventional vaccines are not suited
for use in these environments. A major limitation of conven-
tional vaccination is the requirement for individual inoculation
of each animal (directly or via bait) for induction of immunity,
which is costly and/or impractical for the target species most
frequently involved in high-risk EIDs.[4] Combined with the
anticipated intense competition for vaccine bait by non-target
species, vaccine temperature lability issues [19] may also under-
mine the effectiveness of baiting strategies in hotspot regions –
especially for far-ranging, low population density animals such
as NHPs, which may take several days to come across the
vaccine bait.
Self-disseminating vaccine vectors
Even with programs such as EPT, prediction of which animal
pathogens will become established as globally significant EIDs
within the human population still remains beyond our capabil-
ity. However, pathogens emerging from an animal source are
often initially poorly adapted to their new human host in terms
of sustained human to human transmission.[20] Mechanisms
involved in adaptation are unclear and will presumably be
idiosyncratic to the particular emerging pathogen, but have
been suggested to impart a requirement for repeated introduc-
tions into the human population before a successful adaptation
event results in full human adaptation.[20] This requirement
may provide a potential ‘window of opportunity’ for immuno-
logical targeting of the pathogen within the animal transmission
species, thereby stemming its continued zoonotic flow prior to
acquisition of full adaptation to humans. Self-disseminating
vaccines are a vaccine strategy that may in some instances be
better suited than conventional vaccines to immunologically
contain emerging pathogens within their non-human host in
challenging under-resourced ‘hotspots’. Disseminating vaccines
are designed to exploit the ability of replicating virus-based
vectors to spread through their animal host populations without
the need for direct inoculation of every animal. In this strategy,
vaccination of a limited number of ‘founder’ animals is used for
initial introduction of the vaccine into the target population. As
the vaccine is engineered to express target antigens from the
EID pathogen of interest, its spread from vaccinated to
non-vaccinated animals will result in coordinated spread of
EID-specific immunity throughout the targeted animal
population.
Myxoma virus-based vaccines for myxomatosis and rabbit
hemorrhagic disease virus
The earliest disseminating vaccine for animals was designed
to target two highly lethal rabbit-specific EIDs in the
European rabbit population, myxoma virus (MV) and rabbit
hemorrhagic disease virus (RHDV).[21] The vaccine was
based on a naturally attenuated MV strain (strain 6918)
selected for low virulence (non-lethality), high immunogeni-
city, and maintenance of horizontal transmission.[22]
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MV6918 is essentially identical to the highly pathogenic
wild-type strain except for disruption of four genes, two of
which are known virulence factors.[23] MV6918 was able to
protect against lethal MV challenge following vaccination
using direct inoculation. Importantly, MV6918 was trans-
mitted to >50% of co-housed rabbits (assessed by sero-con-
version), and immunity conferred by transmission was
protective.[22] Onward transmission was less efficient
(approx. 12%) and was no longer protective. MV1698 was
subsequently engineered to express RHDV capsid protein as
a transmissible bi-valent vaccine against both RHD and
myxomatosis.[21,22] Under laboratory conditions, the
MV6918VP60-T2 bivalent vaccine was shown to exhibit
similar characteristics to MV6918. Direct inoculation was
immunogenic and protective in essentially all animals with
>50% transmission from directly inoculated to co-housed
rabbits and a substantial drop in onward transmission.[21]
MV6918VP60-T2 was shown to perform in a remarkably
comparable fashion in a limited field trial performed on an
island with an estimated population of 300 wild European
rabbits with the vaccine showing maintained avirulence,
high immunogenicity following direct inoculation and
>50% transmission rate.[24]
In the above studies, MV was selected as the genetic basis
for the disseminating vaccine due its ability to spread through
rabbit populations. High species specificity of MV for rabbits
also decreased the potential for spread to ‘off-species’ targets
within the environment. However, use of a normally virulent
pathogen for the host species being targeted as the self-disse-
minating vaccine platform necessarily required use of an atte-
nuated MV strain. This requirement had a clear impact on the
disseminating capacity of the MV6918-based vaccine. More
recent self-disseminating vaccine approaches have used cyto-
megalovirus (CMV), which is a beta-herpesvirus, as the dis-
seminating vaccine platform. Similar to MV, CMVs are
immunogenic and spread efficiently through their host spe-
cies.[25–27] However, CMV infection is normally benign in
the healthy host. This important difference removes the need
to use attenuated strains, thereby potentially enabling use of
wild-type CMVs with preserved animal-to-animal transmission
characteristics. Similar to MV, CMVs are also highly species-
restricted with each mammalian host species studied carrying
its own CMV.[25] The species barrier for CMV appears
remarkably robust, with direct experimental inoculation
being unable to establish off-species infection even between
closely related rhesus and cynomolgous macaque CMVs (90%
identical at the nucleotide level).[28] A recent study showed
this strict species restriction to extend to CMVs in the wild,
with the absence of cross-species CMV transmission even
between chimpanzees and monkey prey species involved in
an intimate NHP predator–prey relationship in the Tai
Forest National Park, Cote d’Ivore.[29] CMVs are also ubi-
quitous within their host species,[25] which allows vaccines to
be engineered from CMV strains already endemic within the
target species. This helps remove concerns associated with
introduction of new viruses into animal populations with
which there is no long established biological relationship.
Murine cytomegalovirus-based immunocontraceptive
vaccine for domestic mouse (Mus domesticus) plagues
Although not targeting an EID, over a decade of work toward
the use of a murine CMV (MCMV) as a viral vectored
immunocontraceptive vaccine to control mouse plagues in
Australia gives some insight into the application of disseminat-
ing vaccines to target high risk pathogens for EID control.
Mice directly infected with MCMV strains expressing female
mouse fertility antigens develop prolonged – essentially life-
long – infertility.[30] Immunocontraception was dependent on
antibody production and led to the ablation of ovarian folli-
cles.[31,32] Despite the success of MCMV as an injectable
vaccine, lack of direct transmission to uninfected mice under
laboratory conditions has been a hurdle to its further develop-
ment. Transgene expression by MCMV is frequently associated
with salivary gland attenuation (a major organ involved in
animal-to-animal transmission of CMV). However, even low
passaged, non-genetically manipulated wild-type strains of
MCMV transmit poorly under laboratory conditions.[32]
Therefore, it is not clear if poor transmission of vaccine strains
is due to genetic manipulation of the virus and/or reflects a
general lack of viral transmission under laboratory conditions.
It is possible that the inability to transmit under laboratory
conditions may be due to transmission characteristics unique
to rodent CMVs. Similar to the situation with MCMV in
mice,[33] transmission of Sin Nombre hantavirus (SNV) in
deer mice could not be demonstrated under standard labora-
tory conditions. However, efficient transmission was observed
following co-housing in outdoor enclosures and correlated with
the number of aggressive encounters enumerated by the num-
ber of biting wounds.[34]
Deer mouse CMV-based vaccine to interrupt Sin Nombre
hantavirus zoonotic transmission
The first studies using CMV as a disseminating vaccine
targeting a human EID used CMV from deer mice
(Peromyscus CMV (PCMV)) to target SNV in the wild
deer mouse SNV transmission species. Using a PCMV
expressing the SNV envelope glycoprotein G1, the PCMV
(ΔP33:G1EGFP) vaccine induced G1-specific antibodies fol-
lowing direct inoculation of deer mice.[35] PCMV(ΔP33:
G1EGFP)-induced immunity was durable, persisting over a
12-month period,[36] but was associated with a lower level of
PCMV-specific antibodies compared to the wild-type PCMV.
[35,36] An observed delay in replication in vitro combined
with the lower anti-PCMV antibody levels suggested a level
of attenuation. However, PCMV(ΔP33:G1EGFP) was still
able to induce G1-specific immunity in healthy deer mice
previously infected with either PCMV(ΔP33:G1EGFP) or
wild-type PCMV.[35,36] This ability of CMV to re-infect
the CMV seropositive host is a characteristic shared by other
CMVs, and is critical for use of this virus as a disseminating
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vaccine platform due to CMVs being ubiquitous within their
mammalian hosts.[37] The ability of PCMV(ΔP33:G1EGFP)
to transmit G1-specific immunity in co-housed mice, or to
protect against SNV challenge has not been determined.
However, these studies further suggest the importance of
using a non-attenuated virus-based vaccine platform with
wild-type characteristics, which is possible with CMV given
its benign nature in the healthy host.
CMV-based vaccine to interrupt Ebola virus zoonotic
transmission
A disseminating CMV-based approach is also being developed
toward the control of Ebola virus in wildlife reservoir and
transmission species in Africa.[38,39] Approximately 30% of
past human Ebola virus outbreaks are known to have resulted
from the direct handling of infected ape carcasses,[40] identify-
ing apes as a critical wildlife Ebola virus transmission species.
Ebola virus is also regarded as a major threat to the survival of
African ape populations in the wild.[41] Consequently, a dis-
seminating CMV-based strategy is being developed as part of an
ongoing multidisciplinary effort between human health scien-
tists and the conservationists at the World Wildlife Fund to
target Ebola virus infection in African great apes (bonobo,
chimpanzee and gorilla) and potentially also fruit bats. Fruit
bats (Rousettus aegyptiacus) are also a known reservoir of
Marburg virus [42]; a disseminating vaccine platform targeted
at bat roosts may also therefore be suitable to interrupt trans-
mission of this related filovirus. A recent series of studies have
shown that a CMV-based vaccine is able to provide protection
against Ebola virus challenge following direct inoculation.
[38,39] In these studies, a MCMV vector expressing a
CD8 + T cell epitope from nucleoprotein (NP) of Ebola virus
fused to a non-essential MCMV protein (MCMV/ZEBOV-
NPCTL) was shown to induce durable NP-specific immunity
(>14 months).[38,39] MCMV/ZEBOV-NPCTL vaccinated
mice showed no evidence of Ebola virus disease (EVD) follow-
ing lethal Ebola virus challenge. Impressively, 5/8 mice comple-
tely controlled Ebola virus infection, with no detectable viremia;
the remaining 3 mice showed a 2.8 log reduction in viremia
relative to non-vaccinated controls. Protection was long-lived as
mice vaccinated with a single dose of MCMV/ZEBOV-NPCTL
were protected against EVD following lethal challenge 17 weeks
post-vaccination – an attractive quality for a disseminating
vaccine to be used in wildlife populations. Studies in the NHP
Ebola virus challenge model were recently completed (manu-
script under review). In this model, the key question of trans-
missibility of immunity in CMV seropositive animals (which
cannot be assessed in the laboratory mouse model (see above))
can now be addressed in an experimental system more transla-
table to NHPs in the wild.
Substantial evidence supports the ability of primate CMVs,
including human CMV (HCMV), to superinfect the seropo-
sitive host. A 2008 study examining HCMV seropositive
women showed the frequent presence of multiple glycopro-
tein N (gN) and/or gB variants within HCMV positive urine
and blood samples suggesting that most individuals are
infected with multiple HCMV strains.[43] A subsequent
study monitoring development of HCMV strain-specific anti-
body responses in a cohort of healthy seropositive women
reported 29% of participants developed new strain-specific
antibodies with a mean time of 17.8 months (± 10.3 months)
indicating that superinfection is a relatively common event.
[44] Superinfection of CMV seropositive NHPs has been
demonstrated experimentally in the simian immunodeficiency
virus (SIV):rhesus macaque AIDS model following direct
inoculation of recombinant rhesus CMV (RhCMV) geneti-
cally modified to express SIV antigens.[45] Following super-
infection, recombinant RhCMVs were able to establish
a persistent long-term infection and induced CD4+ and
CD8+ T-cell responses against the expressed SIV antigen
comparable to those observed in RhCMV seronegative ani-
mals.[45] This ability to induce a robust T-cell response
against the ‘new’ heterologous antigen encoded by the
RhCMV vector in the presence of prior CMV immunity is
notable [46] as it suggests that ‘original antigenic sin’ – a
phenomenon first observed for influenza A-specific antibo-
dies,[47] and then for virus-specific T-cell responses in the
lymphocytic choriomeningitis virus mouse model,[48]
whereby the presence of pre-existing immunity blunts the
immune response against a new but cross-reactive antigen –
may not apply in this situation. However, the effect on more
closely antigenically related heterologous target antigens
within the context of CMV infection will need to be
determined.
The studies performed in the SIV:rhesus macaque model
showed that the ability to superinfect was dependent on genes
in the US2-11 region of the genome – a region which contains
several genes involved in down-modulation of MHC class I
antigen presentation.[49] CD8+ T-cell depletion restored the
ability of RhCMVs deleted for US2-11 to superinfect seropo-
sitive animals indicating that superinfection was due to viral
subversion of the host CD8+ T-cell immune response.
Interestingly, following recovery of the CD8+ T-cell response
in these animals, the US2-11 deleted viruses were able
to persist, which indicates that once established, the host
CD8+ T-cell response is unable to clear virus infection.
Outside of the MCMV mouse model (see above), the ability
of recombinant CMVs to spread between animals has not been
tested. However, a recent study investigating transmission of
RhCMV in co-housed animals showed that non-recombinant,
but tissue culture-passaged RhCMV strains maintain an ability
to be shed into bodily fluids (saliva and urine) at levels
comparable to those of wild-type RhCMV, provided that a
region of the genome encoding several genes involved in trop-
ism and immune evasion (called the UL/b’ region) is intact.
[50] CMV transmission is generally believed to involve muco-
sal exposure to such fluids (as well as genital secretions and
breast milk).[25] Consistent with their maintained shedding
characteristics, the tissue culture-passaged viruses also retained
the ability to spread between co-housed RhCMV-seropositive
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Table 1. A non-exclusive list of current emerging zoonotic diseases amenable to targeting with a
self-disseminating vaccine strategy.
Zoonosis Pathogen Incidence Primary
transmission/
reservoir
species
Vector Vaccine Protective
target
antigens
Global Annual Impact
Ebola Virus Sporadic Great apes and
bats (?)
None Yes (E*) GP High lethality and capacity
for spread
Rabies Virus 55,000 deaths/
year
Dogs and
wildlife (bats,
foxes, skunk
and raccoons)
None Yes
Dogs/
Fox
G $583 million [43]
Pandemic/
epidemic
influenza A
Virus Sporadic/annual Pigs and birds
(domestic and
wild)
None Yes
Human/
Fowl
HA/NA $71–167 billion (US,
epidemic) [42]
MERS Virus Sporadic Bats and
dromedary
camels
None Yes (E)
Mice
[53]
S Unknown, but potential
for rapid spread and
significant mortality
Cystic
echinococcosis
(Echinococcus
granulosus)
Cestode
(dog
tapeworm)
Unknown Dogs and sheep None Yes (E)
Sheep/
Dogs
EG95
EgA31
EgTrp
Egms
$1.9 billion (Human-
associated)
$2.1 billion (Livestock)
[44]
Cysticercosis
(Taenia solium)
Cestode
(pig
tapeworm)
2.5 million
>50,000 deaths/
year [47]
Pigs None Yes (E)
Pigs
TSOL18
TSOL45
50% of late-stage
epilepsy attributable to
neurocysticercosis in
endemic areas [46]
Leptospirosis
(Leptospira)
Bacteria 500,000 cases/
year 5–10%
mortality [52]
Multiple
including
rodents and
dogs
None Yes (E)
Hamster
LigA, LigB Unknown
Lassa fever Virus 300,000 cases/
year 2% mortality
[51]
Rodents
(Mastomys
natalensis) [50]
None Yes (E)
NHP
GPC
NP
Unknown
Bovine TB
(Mycobacterium
bovis)
Bacteria Variable, but
increasing
Domestic cattle
and wildlife
(badgers)
None Yes
(human)
Efficacy
unclear
Unknown $160 million (Livestock,
UK) [45]
Chagas disease
(Trpanosoma
cruzi)
Protozoa >10 million,
50–200,000
deaths/year
Dogs and
wildlife
Triato-
mine
bugs
No Unknown $1.3 billion in lost wages/
productivity in Brazil alone
[48]
Acute sleeping
sickness
(Trypanosoma
brucei
rhodesiense)
Protozoa 50–70,000 cases/
year–5% of total
sleeping sickness
disease
(40% cattle in
Uganda are
carriers)
Livestock and
wildlife
Tse fly No Unknown $4.75 billion due to
impact on herd health in
sub-Saharan Africa [49]
Chronic sleeping
sickness
(Trypanosoma
brucei gambiense)
Protozoa 95% of total
sleeping sickness
disease
Livestock and
wildlife, but not
clearly defined
Tse fly No Unknown Unknown
Data taken from Refs: [54–65].
*E = conventional experimental vaccine.
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animals. This observation indicates that it is at least possible
for laboratory manipulated CMV strains to maintain the
ability for wild-type transmission.
Further studies are needed to ensure recombinant CMVs
expressing heterologous target antigens can similarly maintain
wild-type transmission and target-specific immune responses
following transmission. Experience from studies exploring the
use of disseminating vaccines targeting other pathogens (see
above) are expected to prove invaluable for these studies,
especially in regard to the importance of avoiding vaccine
attenuation to maintain wild-type characteristics of CMV
transmissibility. Where studied, frequencies of CMV infection
from natural transmission in animal populations approach
100%. Consistent with epidemiological studies in humans, a
major peak of infection occurs at an early host age, with
essentially all US primate center rhesus macaques being
RhCMV seropositive by the age of one year.[37]
Environmental stresses, such as SIV infection of chimpanzees,
can result in immune suppression of animals in the wild.[51]
It will therefore also be important to ensure that any CMV-
based vaccine presents no higher risk in immune-compromised
animals than the wild-type CMV strains with which they are
already infected.
Expert commentary
It is becoming clear that the emerging pathogens which
represent the greatest risk to global health will most likely
be transmitted from a few key animal species in poorer areas
of the world. Recent history also tells us that these pathogens
will probably have never been seen before. The 2014/2015
Ebola virus outbreak shows the difference healthcare infra-
structure can have on human-to-human transmission of
EIDs. Until the time when overall healthcare infrastructure
in all countries has been raised to a level that enables identi-
fication and control of high-risk EIDs at source, we as a
global community will be fated to reactive responses to EID
outbreaks. Innovative strategies are therefore urgently
required to identify and then pre-emptively control EIDs in
these under-resourced ‘hotspot’ regions. Self-disseminating
vaccination is one innovative approach that may potentially
overcome the problems associated with use of conventional
vaccines for pre-emptive pathogen control in ‘high-value’
animal populations within these challenging environments.
Although still in relatively early stages, the nascent field of
self-disseminating transmissible vaccines has the potential to
solve many current intractable public health and conservation
problems that cannot be addressed by conventional vaccines
(Table 1).
Five-year view
Identification of geographic ‘hotspots’ and ‘high-value’ wild-
life species for EIDs is beginning to enable more informed
decisions over allocation of finite resources to protect global
health.[3,4] In recognition of the change in thinking, the
USAID EPT programs in collaboration with multiple part-
ners aims to ‘monitor for and increase the local capacity in
“geographic hot spots” to identify the emergence of new
infectious diseases in high-risk wildlife such as bats, rodents,
and non-human primates’.[52] Identification of animal
pathogens destined to become significant EIDs within the
human population still remains beyond current technical
capacity. However, the initial poor adaptation of many emer-
ging zoonotic pathogens may provide a window of opportu-
nity during the initial, stuttering transmission phase into
humans enabling the nascent EID to be targeted within its
animal host at a stage when it is still amenable to control.
Following such pathogen identification, a self-disseminating
vaccine platform provides one means to pre-emptively control
the emerging pathogen. Adaptation of new technologies such
as CRISPR/Cas9 will also greatly increase the ease and speed
with which these new vaccine vectors can be constructed
following identification of a target pathogen.[53] The next
five years has the potential to place us in the position of
being able to achieve high vaccine coverage against ‘nascent’
zoonotic pathogens in animal species involved in transmission
that are otherwise inaccessible to conventional vaccination.
For many ‘high-risk’ zoonotic pathogens, this reduction in
zoonotic flow into the human population may decrease the
probability of complete adaption to the human host with
global significance.
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